Abstract Chronic Lymphocytic Leukemia (CLL) is a malignancy of mature B lymphocytes
which are highly dependent on interactions with the tissue microenvironment for their …

B cell receptor (BCR) signaling plays an important pathogenic role in chronic lymphocytic
leukemia (CLL) and B cell lymphomas, based on structural restrictions of the BCR, and BCR …

PURPOSE Nivolumab was assessed in patients with virus-associated tumors in the phase
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …

Purpose: We study CD38 levels in immunosuppressive CD4+ CD25highFoxp3+ regulatory
T cells (Treg) and further define immunomodulating effects of a therapeutic CD38 mAb …

Daratumumab is an anti-CD38 monoclonal antibody with lytic activity against multiple
myeloma (MM) cells, including ADCC (antibody-dependent cellular cytotoxicity) and CDC …

Over the last decade, the active role of the microenvironment in the pathogenesis of B cell
lymphomas has been recognized, delivering signals that favor clonal expansion and drug …

CD38 (also known as T10) was identified in the late 1970s in the course of pioneering work
carried out at the Dana‐Farber Cancer Center (Boston, MA) that focused on the identification …

Immunotherapeutic strategies are emerging as promising therapeutic approaches in
multiple myeloma (MM), with several monoclonal antibodies in advanced stages of clinical …

This review highlights a decade of investigations into the role of CD38 in CLL. CD38 is
accepted as a dependable marker of unfavorable prognosis and as an indicator of activation …

Chronic lymphocytic leukemia (CLL) is an incurable adult disease of unknown etiology.
Understanding the biology of CLL cells, particularly cell maturation and growth in vivo, has …